NEW YORK (360Dx) – HalioDx announced today that it has signed a Mexican distribution deal for its Immunoscore Colon assay with Sohin.
Under the terms of the deal, Sohil will be the assay's exclusive distributor in Mexico. Additional terms were not disclosed.
Immunoscore Colon is designed to quantify CD3+ and CD8+ cell infiltrates in the core tumor and its invasive margin to determine the likelihood cancer will spread or recur after surgery. The assay is performed on formalin-fixed, paraffin-embedded tissue from tumor resections or tumor biopsies and combines immunohistochemistry with a high-resolution image analysis system. According to HalioDx, the test can be used as a tool for patient management based on their intra- and peri-tumor immune response.
Earlier this year, Marseille, France-based HalioDx closed an €18.5 million ($21.7 million) Series B financing round and said it intends to use the proceeds to continue development of Immunoscore Colon and other Immunoscore assays, as well as establish US operations.
In September 2017, the company said it was participating in several new research projects under Franches’ Hospital-University Research in Health program that it believes will allow it to demonstrate the utility of its technologies and may result in new tests based on the Immunoscore platform.